Omeros (NASDAQ:OMER) Stock Rating Lowered by BidaskClub

Omeros (NASDAQ:OMER) was downgraded by BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued to investors on Saturday, BidAskClub reports.

Several other brokerages have also recently weighed in on OMER. Zacks Investment Research raised shares of Omeros from a “sell” rating to a “hold” rating in a research report on Saturday, August 10th. Maxim Group set a $32.00 target price on shares of Omeros and gave the stock a “buy” rating in a research report on Friday, August 9th. ValuEngine cut shares of Omeros from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Wedbush reissued a “neutral” rating and set a $18.00 target price on shares of Omeros in a research report on Monday, July 15th. Finally, HC Wainwright set a $35.00 target price on shares of Omeros and gave the stock a “buy” rating in a research report on Wednesday, September 18th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company’s stock. Omeros currently has a consensus rating of “Hold” and an average target price of $25.80.

Shares of NASDAQ OMER opened at $15.33 on Friday. Omeros has a fifty-two week low of $10.30 and a fifty-two week high of $20.92. The stock has a market cap of $755.62 million, a price-to-earnings ratio of -6.91 and a beta of 2.84. The firm’s 50-day simple moving average is $17.74 and its 200 day simple moving average is $17.41.

Omeros (NASDAQ:OMER) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.44) by $0.15. The business had revenue of $26.80 million during the quarter, compared to the consensus estimate of $25.33 million. During the same period in the previous year, the business posted ($0.70) EPS. Omeros’s revenue was up 1476.5% compared to the same quarter last year. As a group, equities analysts predict that Omeros will post -1.2 EPS for the current fiscal year.

Several institutional investors have recently bought and sold shares of the business. State Board of Administration of Florida Retirement System lifted its position in shares of Omeros by 2.5% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 32,527 shares of the biopharmaceutical company’s stock worth $510,000 after buying an additional 790 shares in the last quarter. Cambridge Investment Research Advisors Inc. increased its stake in shares of Omeros by 8.5% during the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 19,593 shares of the biopharmaceutical company’s stock worth $307,000 after purchasing an additional 1,543 shares during the last quarter. Allianz Asset Management GmbH increased its stake in shares of Omeros by 2.1% during the 2nd quarter. Allianz Asset Management GmbH now owns 76,647 shares of the biopharmaceutical company’s stock worth $1,203,000 after purchasing an additional 1,603 shares during the last quarter. Swiss National Bank increased its stake in shares of Omeros by 2.2% during the 2nd quarter. Swiss National Bank now owns 86,700 shares of the biopharmaceutical company’s stock worth $1,360,000 after purchasing an additional 1,900 shares during the last quarter. Finally, Cypress Capital Group increased its stake in shares of Omeros by 8.3% during the 2nd quarter. Cypress Capital Group now owns 26,000 shares of the biopharmaceutical company’s stock worth $408,000 after purchasing an additional 2,000 shares during the last quarter. 53.13% of the stock is currently owned by hedge funds and other institutional investors.

Omeros Company Profile

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Further Reading: What is the strike price in options trading?

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.